Monday, 20 June 2016

Ocular Melanoma: Randomised phase 2 study of Trametinib +/- GSK2141795 in patients with advanced uveal melanoma

ASCO 2016: Poster Session
Alexander Shoushtari's team have investigated the value of adding an AKT inhibitor (GSK2141795) to the MEK inhibitor drug Trametinib in the expectation that it might mediate against acquired resistance.

Disruption of the MAP kinase pathway (MAPK) has been assoicated with immune response in other tumour types and hence the pursuit of responses with a MEK inhibitor which forms a part of this pathway.

This phase 2 trial concluded that there was no increase in PFS and that objective reponses were rare. Moreover, dose reduction because of side effects were frequent.

No comments:

Post a Comment